Clinical Trials
3 trialsNCT06058377 2026-05-27
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT00450593 2013-08-12
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
National Cancer Institute (NCI)
Unknown
NCT00900354 2013-08-12
Pharmacokinetics of Dactinomycin in Young Patients With Cancer
National Cancer Institute (NCI)
Unknown